Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort

References

• Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875–887. doi:10.1007/s12325-015-0251-z
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
   PubMed Web of Science ®Google Scholar
• Khan AM, Mydra H, Nevarez A. Clinical practice updates in the management of immune thrombocytopenia. Pharm Therap. 2017;42(12):756.
   Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Cuker A, Liebman HA. Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thrombos Haemos. 2021;5(6):e12592, doi:10.1002/rth2.12592
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735. doi:10.1177/2040620719841735
   Web of Science ®Google Scholar
• Deng J, Hu H, Huang F, et al. Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial. Front Pharmacol; 2021:1951.
   Web of Science ®Google Scholar
• Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285–1305. doi:10.1007/s40265-021-01553-7
   PubMed Web of Science ®Google Scholar
• EMC. Eltrombopag SmPC. 2022. Available from: https://www.medicines.org.uk/emc/product/567/smpc#gref.
   Google Scholar
• EMC. Romiplostim SmPC. 2021. Available from: https://www.medicines.org.uk/emc/product/567/smpc#gref.
   Google Scholar
• EMC. Avatrombopag SmPC. 2021. Available from: https://www.medicines.org.uk/emc/product/11837/smpc#gref.
   Google Scholar
• Thachil J, Bagot C, Bradbury C, et al. A United Kingdom immune thrombocytopenia (ITP) forum review of practice: thrombopoietin receptor agonists. Br J Haematol 2018;180(4):591–594. doi:10.1111/bjh.14395
   PubMed Web of Science ®Google Scholar
• González-Porras JR, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906. doi:10.1177/2040620719837906
   Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune Thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol 2021;96(2):188–198. doi:10.1002/ajh.26045
   PubMed Web of Science ®Google Scholar
• McDonald V, Newland A, Morgan M, et al. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). Hematology. 2021;26(1):799–808. doi:10.1080/16078454.2021.1978689
   PubMed Web of Science ®Google Scholar
• Alesci S, Schwan V, Miesbach W, et al. Rare bleeding disorders are associated with depression and anxiety. Hamostaseologie. 2013;33:S64–S68.
   PubMed Web of Science ®Google Scholar
• Jansen A, McDonald V, Newland A, et al. P1636: patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the Netherlands (trapeze nl study). HemaSphere. 2022;6:1517–1518. doi:10.1097/01.HS9.0000849400.99937.5f
   Google Scholar
• Bennett D, Hodgson ME, Shukla A, et al. Prevalence of diagnosed adult immune thrombocytopenia in the United Kingdom. Adv Ther. 2011;28(12):1096–1104. doi:10.1007/s12325-011-0084-3
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Nordon C, Michel M, et al. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016;101(9):1039, doi:10.3324/haematol.2016.146373
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, J American Soc Hemat. 2009;113(11):2386–2393.
   Google Scholar
• [van] Dijk WE, Punt MC, van Galen KP, et al. Menstrual problems in chronic immune thrombocytopenia: a monthly challenge – a cohort study and review. Br J Haematol 2022;198(4):753–764. doi:10.1111/bjh.18291
   PubMed Web of Science ®Google Scholar
• Mansour D, Hofmann A, Gemzell-Danielsson K. A review of clinical guidelines on the management of iron deficiency and iron-deficiency anemia in women with heavy menstrual bleeding. Adv Ther. 2021;38(1):201–225. doi:10.1007/s12325-020-01564-y
   PubMed Web of Science ®Google Scholar
• Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematology/Oncology Clinics. 2009;23(6):1213–1221. doi:10.1016/j.hoc.2009.08.004
   PubMed Web of Science ®Google Scholar
• Terrell DR, Reese J, Branesky D, et al. Depression in adult patients with primary immune thrombocytopenia. Am J Hematol 2016;91(10):E462–E4E3. doi:10.1002/ajh.24484
   PubMed Web of Science ®Google Scholar
• Kruse A, Kruse C, Potthast N, et al. Mental health and treatment in patients with immune thrombocytopenia (ITP); data from the platelet disorder support association (PDSA) patient registry. Blood. 2019;134:2362, doi:10.1182/blood-2019-122278
   Google Scholar
• Tarantino MD, Mathias SD, Snyder CF, et al. Impact of ITP on physician visits and workplace productivity. Curr Med Res Opin. 2010;26(2):319–328. doi:10.1185/03007990903451298
   PubMed Web of Science ®Google Scholar